Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
BMC Pulmonary Medicine
Published in: BMC Pulmonary Medicine 1/2014

Open Access 01-12-2014 | Research article

Genetic variants in ADAM33 are associated with airway inflammation and lung function in COPD

Authors: Xinyan Wang, Wan Li, Kun Huang, Xiaowen Kang, Zhaoguo Li, Chengcheng Yang, Xiaomei Wu, Lina Chen

Published in: BMC Pulmonary Medicine | Issue 1/2014

Login to get access

Abstract

Background

Genetic factors play a role in the development and severity of chronic obstructive pulmonary disease (COPD). The pathogenesis of COPD is a multifactorial process including an inflammatory cell profile. Recent studies revealed that single nucleotide polymorphisms (SNPs) within ADAM33 increased the susceptibility to COPD through changing the airway inflammatory process and lung function.

Methods

In this paper, we investigated associations of four polymorphisms (T1, T2, S2 and Q-1) of ADAM33 as well as their haplotypes with pulmonary function and airway inflammatory process in an East Asian population of patients with COPD.

Results

We found that T1, T2 and Q-1 were significantly associated with the changes of pulmonary function and components of cells in sputum of COPD, and T1 and Q-1 were significantly associated with cytokines and mediators of inflammation in airway of COPD in recessive models. 10 haplotypes were significantly associated with transfer factor of the lung for carbon monoxide in the disease state, 4 haplotypes were significantly associated with forced expiratory volume in one second, and other haplotypes were associated with airway inflammation.

Conclusions

We confirmed for the first time that ADAM33 was involved in the pathogenesis of COPD by affecting airway inflammation and immune response in an East Asian population. Our results made the genetic background of COPD, a common and disabling disease, more apparent, which would supply genetic support for the study of the mechanism, classification and treatment for this disease.
Appendix
Available only for authorised users
Literature
1.
Vestbo J, Hurd SS, Agusti AG, Jones PW, Vogelmeier C, Anzueto A, Barnes PJ, Fabbri LM, Martinez FJ, Nishimura M, Stockley RA, Sin DD, Rodriguez-Roisin R: Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease: GOLD executive summary. Am J Respir Crit Care Med. 2013, 187: 347-365. 10.1164/rccm.201204-0596PP.CrossRefPubMed
2.
Rabe KF, Hurd S, Anzueto A, Barnes PJ, Buist SA, Calverley P, Fukuchi Y, Jenkins C, Rodriguez-Roisin R, van Weel C, Zielinski J: Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease: GOLD executive summary. Am J Respir Crit Care Med. 2007, 176: 532-555. 10.1164/rccm.200703-456SO.CrossRefPubMed
3.
Lokke A, Lange P, Scharling H, Fabricius P, Vestbo J: Developing COPD: a 25 year follow up study of the general population. Thorax. 2006, 61: 935-939. 10.1136/thx.2006.062802.CrossRefPubMedPubMedCentral
4.
Pabst S, Bradler O, Gillissen A, Nickenig G, Skowasch D, Grohe C: Toll-like receptor-9 polymorphisms in sarcoidosis and chronic obstructive pulmonary disease. Adv Exp Med Biol. 2013, 756: 239-245. 10.1007/978-94-007-4549-0_30.CrossRefPubMed
5.
Kim WJ, Oh YM, Lee JH, Park CS, Park SW, Park JS, Lee SD: Genetic variants in HHIP are associated with FEV1 in subjects with COPD. Respirology. 2013, 18: 1202-1209. 10.1111/resp.12139.CrossRefPubMed
6.
Zhou H, Yang J, Li D, Xiao J, Wang B, Wang L, Ma C, Xu S, Ou X, Feng Y: Association of IREB2 and CHRNA3/5 polymorphisms with COPD and COPD-related phenotypes in a Chinese Han population. J Hum Genet. 2012, 57: 738-746. 10.1038/jhg.2012.104.CrossRefPubMed
7.
Bafadhel M, McKenna S, Terry S, Mistry V, Pancholi M, Venge P, Lomas DA, Barer MR, Johnston SL, Pavord ID, Brightling CE: Blood eosinophils to direct corticosteroid treatment of exacerbations of chronic obstructive pulmonary disease: a randomized placebo-controlled trial. Am J Respir Crit Care Med. 2012, 186: 48-55. 10.1164/rccm.201108-1553OC.CrossRefPubMedPubMedCentral
8.
Kojima J, Araya J, Hara H, Ito S, Takasaka N, Kobayashi K, Fujii S, Tsurushige C, Numata T, Ishikawa T, Shimizu K, Kawaishi M, Saito K, Kamiya N, Hirano J, Odaka M, Morikawa T, Hano H, Arai S, Miyazaki T, Kaneko Y, Nakayama K, Kuwano K: Apoptosis inhibitor of macrophage (AIM) expression in alveolar macrophages in COPD. Respir Res. 2013, 14: 30-10.1186/1465-9921-14-30.CrossRefPubMedPubMedCentral
9.
Mallia P, Message SD, Contoli M, Gray KK, Telcian A, Laza-Stanca V, Papi A, Stanciu LA, Elkin S, Kon OM, Johnson M, Johnston SL: Neutrophil adhesion molecules in experimental rhinovirus infection in COPD. Respir Res. 2013, 14: 72-10.1186/1465-9921-14-72.CrossRefPubMedPubMedCentral
10.
Manral S, Bhatia S, Sinha R, Kumar A, Rohil V, Arya A, Dhawan A, Arya P, Joshi R, Sreedhara SC, Gangopadhyay S, Bansal SK, Chatterjee S, Chaudhury NK, Vijayan VK, Saso L, Parmar VS, DePass AL, Prasad AK, Raj HG: Normalization of deranged signal transduction in lymphocytes of COPD patients by the novel calcium channel blocker H-DHPM. Biochimie. 2011, 93: 1146-1156. 10.1016/j.biochi.2011.04.004.CrossRefPubMed
11.
Nadigel J, Audusseau S, Baglole CJ, Eidelman DH, Hamid Q: IL-8 production in response to cigarette smoke is decreased in epithelial cells from COPD patients. Pulm Pharmacol Ther. 2013, 26: 596-602. 10.1016/j.pupt.2013.03.002.CrossRefPubMed
12.
Hubeau C, Kubera JE, Masek-Hammerman K, Williams CM: Interleukin-6 neutralization alleviates pulmonary inflammation in mice exposed to cigarette smoke and poly(I:C). Clin Sci (Lond). 2013, 125: 483-493. 10.1042/CS20130110.CrossRef
13.
Zhang PF, Pan L, Luo ZY, Zhao HJ, Cai SX: Interrelationship of circulating matrix metalloproteinase-9, TNF-a, and OPG/RANK/RANKL systems in COPD patients with osteoporosis. Copd. 2013, 10: 650-656. 10.3109/15412555.2013.813928.CrossRefPubMed
14.
Lee CG, Ma B, Takyar S, Ahangari F, Delacruz C, He CH, Elias JA: Studies of vascular endothelial growth factor in asthma and chronic obstructive pulmonary disease. Proc Am Thorac Soc. 2011, 8: 512-515. 10.1513/pats.201102-018MW.CrossRefPubMedPubMedCentral
15.
Holgate ST, Yang Y, Haitchi HM, Powell RM, Holloway JW, Yoshisue H, Pang YY, Cakebread J, Davies DE: The genetics of asthma: ADAM33 as an example of a susceptibility gene. Proc Am Thorac Soc. 2006, 3: 440-443. 10.1513/pats.200603-026AW.CrossRefPubMed
16.
Chi X, Wang L, Wang J, Li Q, Wang X, Xiao W: Association of ADAM33 gene polymorphisms with asthma in a Chinese population. Clin Respir J. 2013, 7: 16-20. 10.1111/j.1752-699X.2011.00261.x.CrossRefPubMed
17.
Tripathi P, Awasthi S, Prasad R, Ganesh S: Haplotypic association of ADAM33 (T + 1, S + 1 and V - 3) gene variants in genetic susceptibility to asthma in Indian population. Ann Hum Biol. 2012, 39: 479-483. 10.3109/03014460.2012.716451.CrossRefPubMed
18.
Przemyslaw L, Boguslaw HA, Elzbieta S, Malgorzata SM: ADAM and ADAMTS family proteins and their role in the colorectal cancer etiopathogenesis. BMB Rep. 2013, 46: 139-150. 10.5483/BMBRep.2013.46.3.176.CrossRefPubMedPubMedCentral
19.
Miller MA, Meyer AS, Beste MT, Lasisi Z, Reddy S, Jeng KW, Chen CH, Han J, Isaacson K, Griffith LG, Lauffenburger DA: ADAM-10 and -17 regulate endometriotic cell migration via concerted ligand and receptor shedding feedback on kinase signaling. Proc Natl Acad Sci U S A. 2013, 110: E2074-E2083. 10.1073/pnas.1222387110.CrossRefPubMedPubMedCentral
20.
Christian LM: The ADAM family: insights into Notch proteolysis. Fly. 2012, 6: 30-34. 10.4161/fly.18823.CrossRefPubMed
21.
Garlisi CG, Zou J, Devito KE, Tian F, Zhu FX, Liu J, Shah H, Wan Y, Motasim Billah M, Egan RW, Umland SP: Human ADAM33: protein maturation and localization. Biochem Biophys Res Commun. 2003, 301: 35-43. 10.1016/S0006-291X(02)02976-5.CrossRefPubMed
22.
Puxeddu I, Pang YY, Harvey A, Haitchi HM, Nicholas B, Yoshisue H, Ribatti D, Clough G, Powell RM, Murphy G, Hanley NA, Wilson DI, Howarth PH, Holgate ST, Davies DE: The soluble form of a disintegrin and metalloprotease 33 promotes angiogenesis: implications for airway remodeling in asthma. J Allergy Clin Immunol. 2008, 121: 1400-1406. 10.1016/j.jaci.2008.03.003. 1406 e1401–1404CrossRefPubMed
23.
Miyake Y, Tanaka K, Arakawa M: ADAM33 polymorphisms, smoking and asthma in Japanese women: the Kyushu Okinawa Maternal and Child Health Study. Int J Tuberc Lung Dis Off J Int Union Against Tuberc Lung Dis. 2012, 16: 974-979. 10.5588/ijtld.11.0608.CrossRef
24.
Reijmerink NE, Kerkhof M, Koppelman GH, Gerritsen J, de Jongste JC, Smit HA, Brunekreef B, Postma DS: Smoke exposure interacts with ADAM33 polymorphisms in the development of lung function and hyperresponsiveness. Allergy. 2009, 64: 898-904. 10.1111/j.1398-9995.2009.01939.x.CrossRefPubMed
25.
Figarska SM, Vonk JM, van Diemen CC, Postma DS, Boezen HM: ADAM33 gene polymorphisms and mortality. A prospective cohort study. PloS one. 2013, 8: e67768-10.1371/journal.pone.0067768.CrossRefPubMedPubMedCentral
26.
Sadeghnejad A, Ohar JA, Zheng SL, Sterling DA, Hawkins GA, Meyers DA, Bleecker ER: Adam33 polymorphisms are associated with COPD and lung function in long-term tobacco smokers. Respir Res. 2009, 10: 21-10.1186/1465-9921-10-21.CrossRefPubMedPubMedCentral
27.
Gosman MM, Boezen HM, van Diemen CC, Snoeck-Stroband JB, Lapperre TS, Hiemstra PS, Ten Hacken NH, Stolk J, Postma DS: A disintegrin and metalloprotease 33 and chronic obstructive pulmonary disease pathophysiology. Thorax. 2007, 62: 242-247. 10.1136/thx.2006.060988.CrossRefPubMed
28.
van Diemen CC, Postma DS, Vonk JM, Bruinenberg M, Schouten JP, Boezen HM: A disintegrin and metalloprotease 33 polymorphisms and lung function decline in the general population. Am J Respir Crit Care Med. 2005, 172: 329-333. 10.1164/rccm.200411-1486OC.CrossRefPubMed
29.
Wang X, Li L, Xiao J, Jin C, Huang K, Kang X, Wu X, Lv F: Association of ADAM33 gene polymorphisms with COPD in a northeastern Chinese population. BMC Med Genet. 2009, 10: 132-10.1186/1471-2350-10-132.CrossRefPubMedPubMedCentral
30.
Black RA, White JM: ADAMs: focus on the protease domain. Curr Opin Cell Biol. 1998, 10: 654-659. 10.1016/S0955-0674(98)80042-2.CrossRefPubMed
31.
Holz O, Jorres RA, Koschyk S, Speckin P, Welker L, Magnussen H: Changes in sputum composition during sputum induction in healthy and asthmatic subjects. Clin Exp Allergy J Br Soc Allergy Clin Immunol. 1998, 28: 284-292. 10.1046/j.1365-2222.1998.00243.x.CrossRef
32.
Purcell S, Neale B, Todd-Brown K, Thomas L, Ferreira MA, Bender D, Maller J, Sklar P, de Bakker PI, Daly MJ, Sham PC: PLINK: a tool set for whole-genome association and population-based linkage analyses. Am J Hum Genet. 2007, 81: 559-575. 10.1086/519795.CrossRefPubMedPubMedCentral
33.
Holgate ST, Davies DE, Powell RM, Holloway JW: ADAM33: a newly identified protease involved in airway remodelling. Pulm Pharmacol Ther. 2006, 19: 3-11. 10.1016/j.pupt.2005.02.008.CrossRefPubMed
34.
Hashimoto M, Tanaka H, Abe S: Quantitative analysis of bronchial wall vascularity in the medium and small airways of patients with asthma and COPD. Chest. 2005, 127: 965-972. 10.1378/chest.127.3.965.CrossRefPubMed
35.
Winkler AR, Nocka KH, Sulahian TH, Kobzik L, Williams CM: In vitro modeling of human alveolar macrophage smoke exposure: enhanced inflammation and impaired function. Exp Lung Res. 2008, 34: 599-629. 10.1080/01902140802366261.CrossRefPubMed
36.
Domagala-Kulawik J, Maskey-Warzechowska M, Hermanowicz-Salamon J, Chazan R: Expression of macrophage surface markers in induced sputum of patients with chronic obstructive pulmonary disease. J Physiol Pharmacol Off J Pol Physiol Soc. 2006, 57 (Suppl 4): 75-84.
37.
Hackett TL, Stefanowicz D, Aminuddin F, Sin DD, Connett JE, Anthonisen NR, Pare PD, Sandford AJ: Effect of gene environment interactions on lung function and cardiovascular disease in COPD. Int J Chronic Obstructive Pulm Dis. 2011, 6: 277-287.CrossRef
38.
Jongepier H, Boezen HM, Dijkstra A, Howard TD, Vonk JM, Koppelman GH, Zheng SL, Meyers DA, Bleecker ER, Postma DS: Polymorphisms of the ADAM33 gene are associated with accelerated lung function decline in asthma. Clin Exp Allergy J Br Soc Allergy Clin Immunol. 2004, 34: 757-760. 10.1111/j.1365-2222.2004.1938.x.CrossRef
39.
Washko GR, Dransfield MT, Estepar RS, Diaz A, Matsuoka S, Yamashiro T, Hatabu H, Silverman EK, Bailey WC, Reilly JJ: Airway wall attenuation: a biomarker of airway disease in subjects with COPD. J Appl Physiol. 2009, 107: 185-191. 10.1152/japplphysiol.00216.2009.CrossRefPubMedPubMedCentral
40.
Yoshinaka T, Nishii K, Yamada K, Sawada H, Nishiwaki E, Smith K, Yoshino K, Ishiguro H, Higashiyama S: Identification and characterization of novel mouse and human ADAM33s with potential metalloprotease activity. Gene. 2002, 282: 227-236. 10.1016/S0378-1119(01)00818-6.CrossRefPubMed
41.
Kheradmand F, Rishi K, Werb Z: Signaling through the EGF receptor controls lung morphogenesis in part by regulating MT1-MMP-mediated activation of gelatinase A/MMP2. J Cell Sci. 2002, 115: 839-848.PubMedPubMedCentral
42.
Powell RM, Wicks J, Holloway JW, Holgate ST, Davies DE: The splicing and fate of ADAM33 transcripts in primary human airways fibroblasts. Am J Respir Cell Mol Biol. 2004, 31: 13-21. 10.1165/rcmb.2003-0330OC.CrossRefPubMed
43.
Das M, Harvey I, Chu LL, Sinha M, Pelletier J: Full-length cDNAs: more than just reaching the ends. Physiol Genomics. 2001, 6: 57-80.PubMed
44.
Umland SP, Garlisi CG, Shah H, Wan Y, Zou J, Devito KE, Huang WM, Gustafson EL, Ralston R: Human ADAM33 messenger RNA expression profile and post-transcriptional regulation. Am J Respir Cell Mol Biol. 2003, 29: 571-582. 10.1165/rcmb.2003-0028OC.CrossRefPubMed
45.
Siafakas NM, Antoniou KM, Tzortzaki EG: Role of angiogenesis and vascular remodeling in chronic obstructive pulmonary disease. Int J Chronic Obstructive Pulm Dis. 2007, 2: 453-462.
46.
Plataki M, Tzortzaki E, Rytila P, Demosthenes M, Koutsopoulos A, Siafakas NM: Apoptotic mechanisms in the pathogenesis of COPD. Int J Chronic Obstructive Pulm Dis. 2006, 1: 161-171.
47.
Shapiro SD: Vascular atrophy and VEGFR-2 signaling: old theories of pulmonary emphysema meet new data. J Clin Invest. 2000, 106: 1309-1310. 10.1172/JCI11344.CrossRefPubMedPubMedCentral
48.
Paulissen G, Rocks N, Gueders MM, Crahay C, Quesada-Calvo F, Bekaert S, Hacha J, El Hour M, Foidart JM, Noel A, Cataldo DD: Role of ADAM and ADAMTS metalloproteinases in airway diseases. Respir Res. 2009, 10: 127-10.1186/1465-9921-10-127.CrossRefPubMedPubMedCentral
Metadata
Title
Genetic variants in ADAM33 are associated with airway inflammation and lung function in COPD
Authors
Xinyan Wang
Wan Li
Kun Huang
Xiaowen Kang
Zhaoguo Li
Chengcheng Yang
Xiaomei Wu
Lina Chen
Publication date
01-12-2014
Publisher
BioMed Central
Published in
BMC Pulmonary Medicine / Issue 1/2014
Electronic ISSN: 1471-2466
DOI
https://doi.org/10.1186/1471-2466-14-173

Other articles of this Issue 1/2014

BMC Pulmonary Medicine 1/2014 Go to the issue

Research article

mAChRs activation induces epithelial-mesenchymal transition on lung epithelial cells

Research article

Quantitative analysis of lung elastic fibers in idiopathic pleuroparenchymal fibroelastosis (IPPFE): comparison of clinical, radiological, and pathological findings with those of idiopathic pulmonary fibrosis (IPF)

Research article

Nucleotide-oligomerizing domain-1 (NOD1) receptor activation induces pro-inflammatory responses and autophagy in human alveolar macrophages

Research article

Symptoms of depression impact the course of lung function in adolescents and adults with cystic fibrosis

Research article

Phospholipid composition and kinetics in different endobronchial fractions from healthy volunteers

Research article

Pneumococcal pneumonia: differences according to blood culture results
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Pediatric Cardiology Video

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

Cardiopulmonary Comorbidity Video

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Valvular Heart Disease Video

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discuss last year's major advances in heart failure and cardiomyopathies.

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discuss last year's major advances in heart failure and cardiomyopathies.

Watch now

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits